cas 26452-80-2|| where to buy 2,4-Dichloropyridine

Nombre del producto:2,4-Dichloropyridine

IUPAC Name:2,4-dichloropyridine

Unidad de embalaje	Stock disponible	Precio($)
CM102599-100g	in stock	ŢĽ
CM102599-500g	in stock	ǊǊŢ
CM102599-1000g	1-2 Weeks	Ľƞŉ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 26452-80-2 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :26452-80-2; Fórmula molecular:C5H3Cl2N; Punto de fusión:-; Código de sonrisas:ClC1=CC(Cl)=NC=C1; Densidad:

: Número de catálogo:CM102599; Peso molecular:147.99; Punto de ebullición:193.1°C at 760 mmHg; Nº Mdl:MFCD00955618; Almacenamiento:Store at 2-8°C.

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Vimseltinib; Vimseltinib (DCC-3014) is a potent and highly selective oral CSF1R kinase inhibitor that selectively and effectively inhibits CSF1R by utilizing the unique characteristics of the switch control region that regulates kinase conformational activation. The key phase 3 MOTION study conducted by vimseltinib in patients with giant cell tumor of the tendon sheath (TGCT) has shown positive results, and it is expected to submit a listing application to the FDA and the European Union next year.

: Fenebrutinib; Roche’s investigational drug, Fenebrutinib has shown brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis (MS) from the recent release of new data from Phase II FENopta study. Fenebrutinib is a potent and highly selective Bruton’s tyrosine kinase (BTK) inhibitor, and currently the only reversible inhibitor being tested in Phase III MS trials. BTK inhibitor is involved in key pathological features of MS, including B-cell development and activation.